A phase I dose-escalation, pharmacokinetic and pharmacodynamic evaluation of intravenous LY2275796 in patients with advanced cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2012
At a glance
- Drugs ISIS EIF4ERx (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)
- 03 Oct 2006 New trial record.